The Effect of CYP7A1 Polymorphisms on Lipid Responses to Fenofibrate

Overview

Journal J Cardiovasc Pharmacol

Date 2011 Nov 15

PMID 22075751

Citations 11

Authors

Jian Shen

Donna K Arnett

Laurence D Parnell

Chao-Qiang Lai

Robert J Straka

Paul N Hopkins

Ping An

Mary F Feitosa

Jose M Ordovas

Affiliations

Soon will be listed here.

Abstract

Introduction: CYP7A1 encodes cholesterol 7α-hydroxylase, an enzyme crucial to cholesterol homeostasis. Its transcriptional activity is downregulated by fenofibrate. The goal of this study was to determine the effect of CYP7A1 polymorphisms on lipid changes in response to fenofibrate.

Methods: We examined the associations of 3 tagging single nuclear polymorphisms (i6782C>T, m204T>G, 3U12536A>C) at CYP7A1 with triglyceride (TG) and high-density lipoprotein cholesterol (HDL)-C responses to a 3-week treatment with 160 mg/d of fenofibrate in 864 US white participants from the Genetics of Lipid Lowering Drugs and Diet Network study.

Results: The m204T>G variant was significantly associated with TG and HDL-C responses with fenofibrate. Individuals homozygous for the common T allele of m204T>G single nuclear polymorphism displayed both the greater reduction of TG (-32% for TT, -28% for GT, -25% for GG, P = 0.004) and an increase of HDL-C response compared with noncarriers (4.1% for TT, 3.4% for GT, 1.2% for GG, P = 0.01). Conversely, individuals homozygous for the minor allele of i6782C>T showed a greater increase in the HDL-C response compared with noncarriers (2.8% CC, 4.5% for CT, 5.8% for TT, P = 0.02), albeit no significant effect on TG response.

Conclusions: Our data suggest that common variants at the CYP7A1 locus modulate the TG-lowering and HDL-C-raising effects of fenofibrate, and contribute to the interindividual variation of the drug responses.

Citing Articles

Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats.

Vecera R, Poruba M, Huttl M, Malinska H, Oliyarnyk O, Markova I Curr Issues Mol Biol. 2022; 44(5):1889-1900.

PMID: 35678658 PMC: 9164080. DOI: 10.3390/cimb44050129.

Lipopolysaccharide-Induced Transcriptional Changes in LBP-Deficient Rat and Its Possible Implications for Liver Dysregulation during Sepsis.

He Z, Song Z, Meng L, Cheng W, Huang F, Zheng M J Immunol Res. 2022; 2021:8356645.

PMID: 35005033 PMC: 8739918. DOI: 10.1155/2021/8356645.

Quantile-Dependent Expressivity and Gene-Lifestyle Interactions Involving High-Density Lipoprotein Cholesterol.

Williams P Lifestyle Genom. 2020; 14(1):1-19.

PMID: 33296900 PMC: 8116986. DOI: 10.1159/000511421.

Fibrate pharmacogenomics: expanding past the genome.

House J, Motsinger-Reif A Pharmacogenomics. 2020; 21(4):293-306.

PMID: 32180510 PMC: 7202259. DOI: 10.2217/pgs-2019-0140.

Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver Disease.

Jia X, Zhai T Front Endocrinol (Lausanne). 2019; 10:599.

PMID: 31551930 PMC: 6736562. DOI: 10.3389/fendo.2019.00599.

References

Nakamoto K, Wang S, Jenison R, Guo G, Klaassen C, Wan Y . Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet. 2006; 7:29. PMC: 1488870. DOI: 10.1186/1471-2156-7-29. View

Barter P, Rye K . Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol. 2007; 28(1):39-46. DOI: 10.1161/ATVBAHA.107.148817. View

Higgins M . Epidemiology and prevention of coronary heart disease in families. Am J Med. 2000; 108(5):387-95. DOI: 10.1016/s0002-9343(99)00409-x. View

Hofman M, Weggemans R, Zock P, Schouten E, Katan M, Princen H . CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J Nutr. 2004; 134(9):2200-4. DOI: 10.1093/jn/134.9.2200. View

Post S, Groenendijk M, Solaas K, Rensen P, Princen H . Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol. 2004; 24(4):768-74. DOI: 10.1161/01.ATV.0000121572.21122.59. View

Wang S, Du E, MARTIN T, Davis R . Coordinate regulation of lipogenesis, the assembly and secretion of apolipoprotein B-containing lipoproteins by sterol response element binding protein 1. J Biol Chem. 1997; 272(31):19351-8. DOI: 10.1074/jbc.272.31.19351. View

Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang J . Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J Lipid Res. 1998; 39(11):2192-200. View

Angelin B, Einarsson K, Hellstrom K, Leijd B . Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia. J Lipid Res. 1978; 19(8):1004-16. View

Hofman M, Princen H, Zwinderman A, Jukema J . Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clin Sci (Lond). 2005; 108(6):539-45. DOI: 10.1042/CS20040339. View

10.

Post S, Duez H, Gervois P, Staels B, Kuipers F, Princen H . Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001; 21(11):1840-5. DOI: 10.1161/hq1101.098228. View

11.

Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

12.

Machleder D, Ivandic B, Welch C, Castellani L, Reue K, Lusis A . Complex genetic control of HDL levels in mice in response to an atherogenic diet. Coordinate regulation of HDL levels and bile acid metabolism. J Clin Invest. 1997; 99(6):1406-19. PMC: 507957. DOI: 10.1172/JCI119300. View

13.

Birjmohun R, Hutten B, Kastelein J, Stroes E . Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005; 45(2):185-97. DOI: 10.1016/j.jacc.2004.10.031. View

14.

Keech A, Simes R, Barter P, Best J, Scott R, Taskinen M . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500):1849-61. DOI: 10.1016/S0140-6736(05)67667-2. View

15.

Spady D, Cuthbert J, Willard M, Meidell R . Overexpression of cholesterol 7alpha-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. LDL transport and plasma LDL concentrations are reduced. J Biol Chem. 1998; 273(1):126-32. DOI: 10.1074/jbc.273.1.126. View

16.

Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B . Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89(1):147-91. DOI: 10.1152/physrev.00010.2008. View

17.

Russell D, Setchell K . Bile acid biosynthesis. Biochemistry. 1992; 31(20):4737-49. DOI: 10.1021/bi00135a001. View

18.

Lai C, Arnett D, Corella D, Straka R, Tsai M, Peacock J . Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol. 2007; 27(6):1417-25. DOI: 10.1161/ATVBAHA.107.140103. View

19.

Barcelos A, Chies R, Almeida S, Fiegenbaum M, Schweigert I, Chula F . Association of CYP7A1 -278A>C polymorphism and the response of plasma triglyceride after dietary intervention in dyslipidemic patients. Braz J Med Biol Res. 2009; 42(6):487-93. DOI: 10.1590/s0100-879x2009000600003. View

20.

Otvos J . Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol. 1999; 22(6 Suppl):II21-7. PMC: 6655988. DOI: 10.1002/clc.4960221405. View